Deal Flow

Inside the world of M&A, IPOs, and Venture Capital

BLOGS Auto Beat Bangalore Tigers Blogspotting Brand New Day Byte of the Apple Economics Unbound Fine On Media GreenBiz Hot Property Investing Insights Management IQ New Tech in Asia NEXT: Innovation Tools & Trends NussbaumOnDesign Tech Beat Working Parents BLOG RSS FEEDS About RSS

Auto Beat Bangalore Tigers Blogspotting Brand New Day Byte of the Apple Deal Flow Economics Unbound Fine On Media Hot Property Investing Insights New Tech in Asia Nussbaum On Design Tech Beat Working Parents

PREMIUM CONTENT MBA Insider

BW MAGAZINE Get Four Free Issues Register Subscribe Customer Service

ONLINE FEATURES Book Reviews BW Video Columnists Interactive Gallery Newsletters Past Covers Philanthropy Podcasts Special Reports TECHNOLOGY Product Reviews Startups Special Reports Tech Stats Wildstrom: Tech Maven SMALLBIZ Smart Answers Success Stories Today's Tip Trailblazing Companies INVESTING Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Mutual Funds Info Tech 100 S&P 500/BW 50 B-SCHOOLS MBA Profiles MBA Rankings Who's Hiring Grads

BW EXTRAS BW Digital BW Online Alerts Handheld Edition RSS Feeds Reprints/Permissions Conferences Investor Workshops

BUSINESS DIRECTORY

Find local experts in:

« Stealth Startup: mxPlay | Main | iTulip Returns! »

February 28, 2006

Kleiner Perkins' First Pandemic Investment

Justin Hibbard

Kleiner Perkins appears to have made its first investment from its new pandemic fund. True to its plan to invest in late-stage companies, the firm has sunk $12.5 million into publicly traded biopharma company Novavax (NasdaqNM:NVAX), which is developing an avian flu vaccine. The company was a penny stock just six months ago.

12:54 PM

Trackback Pings

TrackBack URL for this entry:
http://blogs.businessweek.com/mt/mt-tb.cgi/

Comments

Post a comment

Copyright 2000-2009, by The McGraw-Hill Companies Inc. All rights reserved.
Terms of Use Privacy Notice